chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I am a 3 year cancer survivor that has neuropathy from chemo. My neuropathy was getting much better until I had the second dose of the Pfizer vaccine.  The pain has intensified in my feet and hands ho; I also have only 50% of my taste and smell since the last vaccine that I was given; I also have only 50% of my taste and smell since the last vaccine; This is a spontaneous report from a contactable consumer (patient).   A 53-year-old female patient received her second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (at the age of 53-years-old) ,  via an unspecified route of administration, administered in the Left arm on 25Feb2021 16:15 (Batch/Lot Number: EN6203) as DOSE 2, SINGLE for COVID-19 immunisation.  Medical history included COVID-19 from an unknown date and unknown if ongoing (patient diagnosed with COVID-19:Yes), cancer survivor  from an unknown date and unknown if ongoing (3 year cancer survivor) and had ongoing neuropathy from chemo. Patient had no known allergies and past drug history. The patient was not pregnant at time of vaccination. Facility where the most recent COVID-19 vaccine was administered in hospital. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. There were no any other medications the patient received within 2 weeks of vaccination. The patient's concomitant medications were not reported. Historical vaccine included BNT162B2  via an unspecified route of administration in the left arm on 04Feb2021 at 16:15 (04:15 PM) (lot number: EN5318) (at the age of 53-years-old) as DOSE 1, SINGLE for COVID-19 immunisation.  The patient reported that she was a 3-year cancer survivor that had ongoing neuropathy from chemo. Her neuropathy was getting much better until she had the second dose of the Pfizer vaccine.  The pain had intensified in her feet and hands horribly (medically significant) on 26Feb2021 06:30. The patient also had only 50% of her  taste and smell since the last vaccine that she was given on 26Feb2021 06:30.  The events did not require treatment.  Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was not recovered.   Follow-up attempts are completed. No further information is expected.
Headache for 48hrs; Sore left deltoid x 3 days; Swollen left deltoid; Body aches; Joint aches; Neck ache; Left axillary lymphadenopathy; Administration date 03Nov2021 at 16:00, dose number=3; This is a spontaneous report from a non-contactable consumer, the patient. A 56-year-old non-pregnant female patient received the third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8841) via an unspecified route of administration in the left arm on 03Nov2021 at 16:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, psoriasis and anxiety. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included adalimumab (HUMIRA), metformin (MANUFACTURER UNKNOWN), empagliflozin (JARDIANCE), atorvastatin calcium (LIPITOR), vitamin d nos (VIT D) and escitalopram (MANUFACTURER UNKNOWN); all taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration on an unknown date and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration on an unknown date as a single dose; both for COVID-19 immunisation. On 04Nov2021 at 01:00, the patient had headache for 48 hours, sore left deltoid for 3 days, swollen left deltoid, body aches, joint aches, neck ache and left axillary lymphadenopathy. The events headache for 48 hours, sore left deltoid for 3 days, swollen left deltoid, body aches, joint aches, neck ache and left axillary lymphadenopathy did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events headache for 48 hours, sore left deltoid for 3 days, swollen left deltoid, body aches, joint aches, neck ache and left axillary lymphadenopathy. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the headache for 48 hours was resolved on 06Nov2021 at 01:00 while sore left deltoid for 3 days was resolved on 07Nov2021. The clinical outcomes of the swollen left deltoid, body aches, joint aches, neck ache and left axillary lymphadenopathy were resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Ct given 0.5 ml dose FLUARIX flu vaccine, ct should of received 0.25 ml based on age.
giant blotch (about 6 X 6) on arm; Blotch inflammed; blotch bumpy under skin; blotch itches bad; wrist pain; fatigue; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (giant blotch (about 6 X 6) on arm), VACCINATION SITE INFLAMMATION (Blotch inflammed), VACCINATION SITE MASS (blotch bumpy under skin), PRURITUS (blotch itches bad) and ARTHRALGIA (wrist pain) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy (Allergy to Thimerosal).    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced VACCINATION SITE PAIN (sore arm). On 01-Apr-2021, the patient experienced ARTHRALGIA (wrist pain) and FATIGUE (fatigue). On 11-Apr-2021, the patient experienced RASH MACULAR (giant blotch (about 6 X 6) on arm), VACCINATION SITE INFLAMMATION (Blotch inflammed), VACCINATION SITE MASS (blotch bumpy under skin) and PRURITUS (blotch itches bad). At the time of the report, RASH MACULAR (giant blotch (about 6 X 6) on arm), VACCINATION SITE INFLAMMATION (Blotch inflammed), VACCINATION SITE MASS (blotch bumpy under skin), PRURITUS (blotch itches bad), ARTHRALGIA (wrist pain), VACCINATION SITE PAIN (sore arm) and FATIGUE (fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided Patient treated her symptoms with allergy pill and aspirin which brought blotch down to (4x4)
She got her vaccine, no prior medical history, no family history of any disease.  She does yoga every day, and got a pain in her side and thought that she pulled a muscle.  She went to her doctor for that, and they ran a D-dimer test on her and it came back very elevated  They proceeded to do chest x-rays to see if she had a pulmonary embolism.  When they did the chest x-rays she was discovered to have nodes in her lungs, some around her heart that are enlarged, some lesions on her spleen which are new, which were not there since December, and some things that are advancing fairly rapidly and no explanation for them.  They were vegans for 5 years, and now every once in a while eat meat.  She does not drink, has never smoked, and worked in an office building and not working some hazardous job site breathing in chemicals.   She had a TB vaccine, and wonders if the vaccine triggers certain things.  She was put on Aricept to dilate her lungs so that she could have more breathing capacity and wanted to put her on a steroid one and got thrush within 24 hours from that.  Prednisone is the only other thing, and an expectorant for the cough.  She had  a biopsy in November and suspected she had sarcoidosis, and had a PET scan at the end of November.  She had the official diagnosis on 1/4/23 of sarcoidosis.   She had another PET scan done last Friday and has had an increase in size and new nodules in 2 months.  Her doctor wants her to come in on Thursday to go over what the next step in this disease.   She now has the sarcoid rash and are exactly where they start in her joints, ankles and elbow joints which is were everything is occurring.   It is progressing rapidly for the disease itself.  Some live for 25 years, but she is not even in the age group for this disease.  Everything about her disease process just does not make sense.    The initial thought she had lung cancer, and has had endoscopies, PET scans, etc.  They checked her for valley fever, TB tests and multiple testing.  Sleeping is a chore now as she cannot lie down without coughing.  They are now testing her heart as it affects her heart, lungs, brain and goes to different organs through the lymph system.  Right now she has pain in her groin and dragging her left leg due to the pain and stiffness, and can feel the lumps and knows that her nodes are swollen there.
Racing heart; Nausea; This spontaneous case was reported by a pharmacist and describes the occurrence of PALPITATIONS (Racing heart) and NAUSEA (Nausea) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041J21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In December 2021, the patient experienced PALPITATIONS (Racing heart) and NAUSEA (Nausea). At the time of the report, PALPITATIONS (Racing heart) and NAUSEA (Nausea) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported by reporter No treatment medications provided by the reporter.     This case was linked to MOD-2021-436217 (Patient Link).
pt recv vax & devel soreness @ the inj site (lasting 36-48hr) & h/a;pt exp redness & swelling from the inj site to the elbow & pain;dx cont for 3 days a/beginning to subside;
Redness area approximate 4 inches wide noted as "covid vaccine arm".  No itching, no pain  but affected area warm to touch.   This appeared getting bigger about a week after injection with no other side effect.
injection site was still a little sore; Muscle sore on neck and shoulders; Muscle sore on neck in both sides,scle sore on shoulders; fingers started tingling and weak; all of a sudden neck fot kind of tied and weak; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (fingers started tingling and weak), MUSCULAR WEAKNESS (all of a sudden neck fot kind of tied and weak), VACCINATION SITE PAIN (injection site was still a little sore), ARTHRALGIA (Muscle sore on neck and shoulders) and MYALGIA (Muscle sore on neck in both sides,scle sore on shoulders) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.    Co-suspect product included non-company product LEVOTHYROXINE SODIUM (SYNTHROID) for an unknown indication.    Concomitant products included CALCIUM and FISH OIL (OMEGA 3 6 9 [FISH OIL]).   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started LEVOTHYROXINE SODIUM (SYNTHROID) (unknown route) at an unspecified dose. On 18-Jan-2021, the patient experienced PARAESTHESIA (fingers started tingling and weak), MUSCULAR WEAKNESS (all of a sudden neck fot kind of tied and weak), ARTHRALGIA (Muscle sore on neck and shoulders) and MYALGIA (Muscle sore on neck in both sides,scle sore on shoulders). On an unknown date, the patient experienced VACCINATION SITE PAIN (injection site was still a little sore). At the time of the report, PARAESTHESIA (fingers started tingling and weak), MUSCULAR WEAKNESS (all of a sudden neck fot kind of tied and weak), VACCINATION SITE PAIN (injection site was still a little sore), ARTHRALGIA (Muscle sore on neck and shoulders) and MYALGIA (Muscle sore on neck in both sides,scle sore on shoulders) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021; Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Nov-2021 at 11:06 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 03-Nov-2021 at 11:06 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patients where administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient age was given as 87.06 Concomitant products were not reported.  On 03-Nov-2021, Excursion time was 10 AM, temperature was 35, total doses given for the day was 117, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 05-Oct-2021, vial was moved to clinic on 03-Nov-2021. 06 vials were sent to clinic. Vaccine BUD date was 05-Nov-2021.  Vial was stored on cooler 1, on 03-Nov-2021, Excursion duration At 8 AM: 36, 9 AM: 36, 10 AM: 36, 11 AM: 35, 12 AM: 36, 1PM: 37, 2 PM: 36, 3 PM: 36, 4 PM: 37 and 5 PM: 42.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic. Temperature recordings were taken using a Fisherbrand traceable temperature monitor at every hour. After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
Sore arms, loss of swallowing in January, 2022, eventual Dermatomyositis diagnosis
received 1st dose of the Moderna COVID-19 vaccine from a vial that had been first punctured on 07Jul2021 @ 3:42p with the syringe having been at room temperature approximately 24 hours when administered.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received 1st dose of the Moderna COVID-19 vaccine from a vial that had been first punctured on 07Jul2021 @ 3:42p with the syringe having been at room temperature approximately 24 hours when administered.) in a 37-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (received 1st dose of the Moderna COVID-19 vaccine from a vial that had been first punctured on 07Jul2021 @ 3:42p with the syringe having been at room temperature approximately 24 hours when administered.). On 08-Jul-2021, EXPIRED PRODUCT ADMINISTERED (received 1st dose of the Moderna COVID-19 vaccine from a vial that had been first punctured on 07Jul2021 @ 3:42p with the syringe having been at room temperature approximately 24 hours when administered.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 09-Jul-2021: Follow up received on 09-Jul-2021 and does not contain any new information.
This spontaneous report as received from a licensed practical nurse refers to a 12 year old patient of unknown gender. No information regarding the patient's medical history, concurrent conditions or concomitant medications was reported. On 31-AUG-2015, the patient was vaccinated with a dose of GARDASIL 9 lot # L007560 (dose, route of administration and expiration date were not reported) that has experienced temperature excursion. No adverse reaction was reporter. This is one of several reports received form the same reporter. Additional information has been requested.
This case was reported by a nurse and described the occurrence of vaccine underdose in a 31-year-old female patient who received ENGERIX B. On 3rd November 2014, the patient received the 1st dose of ENGERIX B 10 micrograms. On 3rd November 2014, an unknown time after receiving ENGERIX B, the patient experienced vaccine underdose. On an unknown date, the outcome of the vaccine underdose was unknown. Additional information: 31-year-old female was given 10 mcg of ENGERIX-B inadvertently by a new staff nurse, instead of 20 mcg adult dose.
Severe aggravation of pre-existing Herpes Simplex, ?cold sores? on lips.  Acquired prescription for Acyclovir for treatment.
tinnitus that hasn't subsided, worse in the mornings around 9:00am-12:00pm, worse at night while lying down
No adverse effects noted. Patient received COVID-19 vaccine along with other vaccines on the same day.
Double vision, weakness & pain in feet, hands, arms, legs & back; Periods of sweating & aching; loss of sleep; loss of weight; 13th in 1 wk; numbness in hands & feet;
2 3/4'' x 3''  Redness began 08/22/2002, increased until 08/26/2002. Seen by MD 08/27/2002- improved 08/28/2002.
Difficulty with sleep.  Awake at 2:00 AM and unable to fall asleep.  Felt similar to side effect of prednisone and levaquin.
Client reports lightheadedness and general weakness 1 hour post vaccination, lasting 2 hours before resolving.  Client did not take any medication, no interventions.  Client did not follow up with primary care provider.
Extreme fatigue, headache, congestion, sneezing, shaking hands. I slept on and off for more than 48 hours.
Slight rash after 1st dose, severe rash after 2nd dose with body aches, headache, tiredness.
1-2 weeks after receiving MMR, began having rashes on legs which spread to entire body. Frequently sick with colds. Has been under treatment since. Tested for syphilis, AIDS, etc--all negative. Doctor told him "non-specific" disorder, related to vaccine. Caused immune system breakdown.
developed erythema from the injection site down to her elbow; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE ERYTHEMA (developed erythema from the injection site down to her elbow) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On 30-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (developed erythema from the injection site down to her elbow). At the time of the report, VACCINATION SITE ERYTHEMA (developed erythema from the injection site down to her elbow) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
The night of the injection I came down with a fever or 100.8 that would not subside with Tylenol or ibuprofen. It did lower temporarily but went right back up and lasted 24 hours. I also had nausea, swollen glands, headache, and body aches.      24 hours after the start of symptoms, my fever has subsided. I still have a slight head ache and general malaise, but I am able to work today.
Severe itching in both hands on the top and bottom as well as both feet. This started 28 hrs after receiving the vaccine.
Caller had myocarditis and pericarditis; Caller had myocarditis and pericarditis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (005570). The reporter is the patient.  A 32 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single, for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included Covid-19 vaccine (Dose: 1, Manufacturer unknown), for COVID-19 Immunization. The following information was reported MYOCARDITIS (medically significant), PERICARDITIS (medically significant), outcome recovered. The event caller had myocarditis and pericarditis and caller had myocarditis and pericarditis was evaluated at the emergency room visit. The caller received the second dose Pfizer Covid Vaccine and had a horrible reaction. The caller ended up in the hospital and had myocarditis and pericarditis. He was transported via ambulance to the emergency room and was in the emergency room for 6 or 7 hours until sorted out.   Follow-up attempts have been completed and no further information is expected.
The expired vial was labeled as COVID 19 Vaccine / Janssen 0.5ml / EXP: 6/23/21 @ opened 2:15 This vial was used for a Veteran on 6/24/21 @ 1043
5inch red & swollen area to lt deltoid; fever of 104, cried all noc p/vax; woke up once per hr; 2 nights p/vax missed 3 days of school; given APAP;
Patient given Flucelvax Quad on 9/10/2020 at 12:30pm by me. No signs or symptoms.
side effects from the booster; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION COMPLICATION (side effects from the booster) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (side effects from the booster). At the time of the report, VACCINATION COMPLICATION (side effects from the booster) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided.  No treatment  medication was provided.   Reporter did not allow further contact